Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group

[1]  M. Matucci-Cerinic,et al.  Effects of rituximab in connective tissue disorders related interstitial lung disease. , 2016, Clinical and experimental rheumatology.

[2]  M. Baron,et al.  Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial , 2016, The Lancet.

[3]  D. Furst,et al.  Update of EULAR recommendations for the treatment of systemic sclerosis , 2015, Annals of the rheumatic diseases.

[4]  M. Moradi-Lakeh,et al.  Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement—a retrospective study , 2014, Rheumatology International.

[5]  P. Sfikakis,et al.  Mycophenolate Versus Cyclophosphamide for Progressive Interstitial Lung Disease Associated with Systemic Sclerosis: A 2-Year Case Control Study , 2013, Lung.

[6]  D. Hansell,et al.  Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis , 2013, The Journal of Rheumatology.

[7]  J. Pope,et al.  Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts. , 2012, Seminars in arthritis and rheumatism.

[8]  U. Schneider,et al.  Responders to cyclophosphamide: results of a single-centre analysis among systemic sclerosis patients , 2012, Annals of the rheumatic diseases.

[9]  A. Oikonomou,et al.  Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis , 2012, Pulmonary medicine.

[10]  Chi-Hong Tseng,et al.  Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. , 2011, Arthritis and rheumatism.

[11]  L. Mouthon,et al.  Therapeutic options for systemic sclerosis related interstitial lung diseases. , 2010, Respiratory medicine.

[12]  A. Ziogas,et al.  Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease , 2010, Clinical Rheumatology.

[13]  R. Landewé,et al.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) , 2009, Annals of the rheumatic diseases.

[14]  P. Erwin,et al.  Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies , 2008, Arthritis research & therapy.

[15]  R. Elashoff,et al.  Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. , 2007, American journal of respiratory and critical care medicine.

[16]  G. Valentini,et al.  Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. , 2007, Clinical and experimental rheumatology.

[17]  C. Denton,et al.  Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. , 2007, Rheumatology.

[18]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[19]  Vinod K. Sharma,et al.  Evaluation of oral methotrexate in the treatment of systemic sclerosis , 2007, International journal of dermatology.

[20]  U. Müller-Ladner,et al.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.

[21]  P. Emery,et al.  A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.

[22]  S. Liossis,et al.  Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. , 2006, Rheumatology.

[23]  M. Fritzler,et al.  A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis , 2006, Clinical Rheumatology.

[24]  Y. Nakajima,et al.  Methotrexate-Induced Pulmonary Injury: Serial CT findings , 2003, Journal of thoracic imaging.

[25]  A. Silman,et al.  Predictors of end stage lung disease in a cohort of patients with scleroderma , 2003, Annals of the rheumatic diseases.

[26]  T. Medsger,et al.  Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. , 1998, Arthritis and rheumatism.

[27]  F. V. D. van den Hoogen,et al.  Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. , 1996, British journal of rheumatology.

[28]  T. Medsger,et al.  Severe restrictive lung disease in systemic sclerosis. , 1994, Arthritis and rheumatism.

[29]  G. Raghu,et al.  Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. , 1991, The American review of respiratory disease.

[30]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[31]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[32]  J. Bijlsma,et al.  Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review. , 2013, Clinical and experimental rheumatology.